| 0 (0%) | 09-27 09:27 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 20.26 |
1-year : | 23.66 |
| Resists | First : | 17.35 |
Second : | 20.26 |
| Pivot price | 15.72  |
|||
| Supports | First : | 15.57 |
Second : | 14.47 |
| MAs | MA(5) : | 15.56 |
MA(20) : | 15.78 |
| MA(100) : | 15.79 |
MA(250) : | 20.27 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 44.3 |
D(3) : | 32.8 |
| RSI | RSI(14): 54.5 |
|||
| 52-week | High : | 32.09 | Low : | 12.72 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ IMVT ] has closed below upper band by 28.3%. Bollinger Bands are 8.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 16.53 - 16.6 | 16.6 - 16.66 |
| Low: | 15.39 - 15.47 | 15.47 - 15.54 |
| Close: | 16.11 - 16.22 | 16.22 - 16.34 |
Sat, 27 Sep 2025
Banque Pictet & Cie SA Has $2.02 Million Stock Holdings in Immunovant, Inc. $IMVT - MarketBeat
Mon, 22 Sep 2025
Interesting IMVT Put Options For November 21st - Nasdaq
Wed, 10 Sep 2025
Immunovant (IMVT) Valuation in Focus Following New Batoclimab Clinical Data Announcement - simplywall.st
Wed, 10 Sep 2025
Immunovant (IMVT) Up 7.8% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Wed, 03 Sep 2025
$IMVT stock is up 8% today. Here's what we see in our data. - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 174 (M) |
| Shares Float | 67 (M) |
| Held by Insiders | 57 (%) |
| Held by Institutions | 55.5 (%) |
| Shares Short | 15,570 (K) |
| Shares Short P.Month | 16,430 (K) |
| EPS | -2.84 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.55 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -47.1 % |
| Return on Equity (ttm) | -77.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.71 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -417 (M) |
| Levered Free Cash Flow | -256 (M) |
| PE Ratio | -5.72 |
| PEG Ratio | 0 |
| Price to Book value | 4.55 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.79 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|